U.S. Markets closed

Hemispherx Biopharma, Inc. (HEB)


NYSE MKT - NYSE MKT Delayed Price. Currency in USD
Add to watchlist
0.485-0.00 (-1.02%)
At close: 4:02PM EDT
People also watch
GNBTCVMCTICBCRXVICL
Full screen
Previous Close0.490
Open0.500
Bid0.000 x
Ask0.000 x
Day's Range0.470 - 0.500
52 Week Range0.390 - 2.640
Volume69,204
Avg. Volume235,330
Market Cap12.9M
Beta-0.61
PE Ratio (TTM)-1.37
EPS (TTM)-0.35
Earnings DateMay 18, 2017 - May 19, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.52
Trade prices are not sourced from all markets
  • Capital Cube9 days ago

    ETFs with exposure to Hemispherx Biopharma, Inc. : June 16, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Hemispherx Biopharma, Inc. Here are 5 ETFs with the largest exposure to HEB-US. Comparing the performance and risk of Hemispherx Biopharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Hemispherx Biopharma, Inc. :HEB-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
    Capital Cube23 days ago

    Hemispherx Biopharma, Inc. :HEB-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017

    Categories: Yahoo FinanceGet free summary analysis Hemispherx Biopharma, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Hemispherx Biopharma, Inc. – Sarepta Therapeutics, Inc., Gilead Sciences, Inc., Pfizer Inc., Baxter International Inc., Merck & Co., Inc., Valeant Pharmaceuticals International Inc, GlaxoSmithKline plc Sponsored ADR and ... Read more (Read more...)

  • GlobeNewswire25 days ago

    Hemispherx Biopharma Repurposes Ampligen in Immuno-Oncology

    PHILADELPHIA, May 31, 2017-- Hemispherx Biopharma announced today that it continues to bolster its scientific capabilities by expanding the role of Joseph C. Horvath, M.D., to Deputy Chief Medical Officer.. ...